PORCINE SECRETIN
LOE Approachingporcine secretin
NDASUBCUTANEOUS LYOPHILIZED POWERINJECTABLEPriority Review
Approved
Apr 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Porcine secretin is a peptide hormone derived from porcine pancreatic tissue, administered as a subcutaneous lyophilized injectable. It was approved in 2002 but lacks publicly disclosed indications in this dataset, suggesting it may be used for specialized diagnostic or therapeutic gastroenterological applications. The drug acts as a secretin analog to stimulate pancreatic and biliary secretion.
LOE Approaching
With LOE approaching and no disclosed Part D spending, this niche injectable faces imminent generic/biosimilar competition; commercial teams likely operate with small, specialized field footprints.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities on porcine secretin are limited due to zero linked job postings and its niche market position. Roles available are typically within small, specialized teams managing a mature injectable in a low-growth therapeutic area.
Specialty Pharmaceutical SalesProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.